Bioequivalence and Bioavailability Forum

Main page Policy/Terms of Use Abbreviations Latest Posts

 Log-in |  Register |  Search

Back to the forum  Query: 2017-03-23 09:13 CET (UTC+1h)

Highly Variable Drug BE Justification [Regulatives / Guidelines]

posted by ElMaestro - Denmark, 2017-03-20 06:55  - Posting: # 17167
Views: 260

Hi jag009,

» What if one conducted pilot studies and found that the ISCV is like 28/29%? My concensus still would be to proceed with RSABE approach since the it is a mixed approach which allows both RSABE(if Ref SD<0.294) and ABE analysis(if Ref SD>0.294)

That's valid, but if you are not really sure if you are just "borderline" then the additional overhead associated with the replicated design may not be worth it. You find an intra-CVR of 31%, and you scale the limits a wee bit etc. But the price you paid for this moderate scaling option could be much higher than you'd be paying for a conventional 222BE trial with a few extra volunteers. Would be interesting to discuss an objective function here :-)

This isn' the answer, but just a view.

I could be wrong, but…

Best regards,

Here's the good news, folks: If you leave operational excellence, (c)LEAN, six sigma and management consultancy firms out of your development programmes, then you may have a chance to be first to market and to beat your competitors.

Complete thread:

Back to the forum Activity
 Mix view
Bioequivalence and Bioavailability Forum | Admin contact
16,685 Posts in 3,582 Threads, 1,009 registered users;
18 users online (0 registered, 18 guests).

Anyone who has never made a mistake
has never tried anything new.    Albert Einstein

BEBAC Ing. Helmut Schütz